REMEGEN
- Country
- ๐ญ๐ฐHong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: RC18 80 mg plus standard therapyBiological: RC18 160 mg plus standard therapyBiological: Placebo plus standard therapyBiological: RC18 240 mg plus standard therapy
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 249
- Registration Number
- NCT02885610
- Locations
- ๐จ๐ณ
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-ฮฑ Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
- Conditions
- Moderate and Severe Rheumatoid Arthritis
- Interventions
- Drug: Placebo plus MTXDrug: RC18 160 mg plus MTX
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02882087
- Locations
- ๐จ๐ณ
Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02881138
- Locations
- ๐จ๐ณ
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT02881190
- Locations
- ๐จ๐ณ
Beijing Cancer Hospital, Beijing, Beijing, China